JP2009514786A - 腎結石及び骨粗鬆症の処置のためのクエン酸カリウムカルシウムの粉末混合物 - Google Patents

腎結石及び骨粗鬆症の処置のためのクエン酸カリウムカルシウムの粉末混合物 Download PDF

Info

Publication number
JP2009514786A
JP2009514786A JP2008521643A JP2008521643A JP2009514786A JP 2009514786 A JP2009514786 A JP 2009514786A JP 2008521643 A JP2008521643 A JP 2008521643A JP 2008521643 A JP2008521643 A JP 2008521643A JP 2009514786 A JP2009514786 A JP 2009514786A
Authority
JP
Japan
Prior art keywords
calcium
citrate
potassium
meq
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008521643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009514786A5 (enExample
Inventor
チャールズ ワイ． シー． パク，
カーシェイヤー サケイー，
ニール ビー． ウォルスドルフ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2009514786A publication Critical patent/JP2009514786A/ja
Publication of JP2009514786A5 publication Critical patent/JP2009514786A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2008521643A 2005-07-15 2006-07-13 腎結石及び骨粗鬆症の処置のためのクエン酸カリウムカルシウムの粉末混合物 Pending JP2009514786A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/183,140 US20070077314A1 (en) 2005-07-15 2005-07-15 Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
PCT/US2006/027398 WO2007011740A2 (en) 2005-07-15 2006-07-13 A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis

Publications (2)

Publication Number Publication Date
JP2009514786A true JP2009514786A (ja) 2009-04-09
JP2009514786A5 JP2009514786A5 (enExample) 2009-06-25

Family

ID=37669400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008521643A Pending JP2009514786A (ja) 2005-07-15 2006-07-13 腎結石及び骨粗鬆症の処置のためのクエン酸カリウムカルシウムの粉末混合物

Country Status (5)

Country Link
US (2) US20070077314A1 (enExample)
EP (1) EP1922064A4 (enExample)
JP (1) JP2009514786A (enExample)
AU (1) AU2006270162B2 (enExample)
WO (1) WO2007011740A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278112B2 (en) * 2013-03-15 2016-03-08 New York University Citrate containing beverage
US9529465B2 (en) * 2013-12-02 2016-12-27 At&T Intellectual Property I, L.P. Secure interaction with input devices
US20150216825A1 (en) * 2014-02-06 2015-08-06 University Of Houston System Organic acids as growth inhibitors of pathological calcification and uses thereof
US10285961B2 (en) 2014-02-06 2019-05-14 University Of Houston System Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof
CN104069125B (zh) * 2014-07-16 2017-02-08 华南理工大学 一种用于泌尿系磷酸盐结石的溶石剂及其制备方法
WO2016159897A1 (en) * 2015-04-01 2016-10-06 Ay Doğan Potassium citrate suspension
WO2019035989A1 (en) * 2017-08-17 2019-02-21 The Board Of Regents Of The University Of Texas System PREVENTION OF CALCIUM OXALATE RENAL CALCULATIONS BY POTASSIUM HYDROXYCITRATE
IT202200021258A1 (it) * 2022-10-14 2024-04-14 Neilos S R L “Composizione nutraceutica o farmaceutica per il benessere renale”

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504384A (ja) * 1999-07-19 2003-02-04 ミッション・ファーマカル・カンパニー クエン酸カリウムカルシウム組成物および製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888182A (en) * 1983-04-11 1989-12-19 Board Of Regents Of The University Of Texas System Compositions and methods of treating calcium renal stones
US4772467A (en) * 1985-02-19 1988-09-20 Board Of Regents, U T Systems Osteoporosis inhibition by dietary calcium supplementation
US4722847A (en) * 1986-05-07 1988-02-02 The Procter & Gamble Company Fruit juice beverages and juice concentrates nutritionally supplemented with calcium
US4871554A (en) * 1987-08-12 1989-10-03 Coca-Cola Company Calcium fortified food product
US5128374A (en) * 1987-08-28 1992-07-07 The Procter & Gamble Company Use of calcium citrate malate for the treatment of osteoporosis and related disorders
ES2061394B1 (es) * 1993-02-05 1995-06-16 Robert S A Lab Procedimiento de fabricacion de un granulado de citrato potasico con cesion retardada.
US6680305B1 (en) * 1993-06-04 2004-01-20 Biotime, Inc. Physiologically acceptable aqueous solutions and methods for their use
DE19503190A1 (de) * 1995-02-01 1996-08-08 Dietl Hans Mittel zur Beeinflussung von Störungen der Knochenbildung
GB9603518D0 (en) * 1996-02-20 1996-04-17 Smithkline Beecham Plc Novel process
US6599544B2 (en) * 2000-01-26 2003-07-29 American Micronutrients, Inc. Calcium enrichment composition and method for producing the same
BR0114988A (pt) * 2000-10-16 2004-02-03 Pepsico Inc Bebidas suplementadas com cálcio e métodos para fabricá-las
US20030175360A1 (en) * 2002-02-22 2003-09-18 Renzo Luzzatti Symptomatic relief of gastrointestinal disorders
US7507421B2 (en) * 2002-04-30 2009-03-24 Unibar Corporation Hydroxycitric acid salt composition and method of making
US6833146B2 (en) * 2002-07-08 2004-12-21 Unilab Pharmatech, Ltd. Powered beverage mix with rapidly dissolving calcium
US7138151B2 (en) * 2002-11-22 2006-11-21 Unilab Pharmatech, Ltd. Calcium-fortified acidic beverages
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504384A (ja) * 1999-07-19 2003-02-04 ミッション・ファーマカル・カンパニー クエン酸カリウムカルシウム組成物および製造方法

Also Published As

Publication number Publication date
AU2006270162B2 (en) 2012-01-12
US20070077314A1 (en) 2007-04-05
AU2006270162A1 (en) 2007-01-25
EP1922064A4 (en) 2010-12-22
WO2007011740A2 (en) 2007-01-25
US20100227006A1 (en) 2010-09-09
US8216614B2 (en) 2012-07-10
WO2007011740A3 (en) 2009-04-30
EP1922064A2 (en) 2008-05-21

Similar Documents

Publication Publication Date Title
JP2614909B2 (ja) カルシウム化合物およびクエン酸の易溶性混合物からの液体カルシウム補充
Pak Citrate and renal calculi: new insights and future directions
US8216614B2 (en) Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
JP5049589B2 (ja) ストロンチウム塩含有の放出制御組成物
AU576950B2 (en) Liquid dietary calcium supplementation
RU2541092C2 (ru) Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией
HU208923B (en) Process for producing pharmaceutical compositions for treating osteoporosis containing pharmaceutically applicable alkalizing potassium salt
CZ20032880A3 (cs) Použití sloučenin vzácných zemin pro prevenci ledvinových kamenů
US20040048925A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040220266A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
Butz Rational prevention of calcium urolithiasis
AU2018327614B2 (en) Composition for calcium supplementation
WO1991016909A1 (en) Pharmaceutical composition
Wu et al. Effects of magnesium citrate and phytin on reducing urinary calcium excretion in rats
EP2234482B1 (en) Sulfate salt prophylaxis and therapies
US12251400B2 (en) Liquid concentrates of calcium and magnesium
Abrahams et al. Urinary Stone Inhibitors: Citrate and Magnesium
US20200078395A1 (en) Averting complications of pump inhibitor therapy by effervescent calcium magnesium citrate
US20110269837A1 (en) Phosphorus binder composition for treatment of hyperphosphatemia
SHLAFER et al. 27 Drug therapy and nutrition
CN102232964A (zh) 治疗泌尿系统结石及高尿酸血症的药
Reddi Disorders of Mineral Metabolism and Nephrolithiasis
Chernenko What is an antacid. List of antacid drugs: classification, rules of admission, side effects
Chernenko What is an antacid agent. List of antacid drugs: classification, reception rules, side effects

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100422

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120705